Bio-Technology General Corporation
Records under this name other than patents Bio-Technology General Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Bio-Technology General Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,610,520 | Gene encoding human manganese superoxide dismutase and recombinant polypeptide encoded thereby Formerly held Term ended Term ended Aug 26, 2020 · From the USPTO record | Term ended | Term ended Aug 26, 2020 | From the USPTO record |
| US 6,576,659 | Use of oxandrolone in the treatment of burns an other wounds Formerly held Term ended Term ended Dec 5, 2017 · From the USPTO record | Term ended | Term ended Dec 5, 2017 | From the USPTO record |
| US 6,828,313 | Use of Oxandrolone in the Treatment of Burns and Other Wounds Formerly held Term ended Term ended Dec 5, 2017 · Medium confidence | Term ended | Term ended Dec 5, 2017 | Medium confidence |
| US 6,054,291 | Expression vectors for enhanced production of polypeptides, plasmids containing the vectors, hosts containing the plasmids, products manufactured thereby and related methods Formerly held Term ended Term ended Jun 9, 2017 · From the USPTO record | Term ended | Term ended Jun 9, 2017 | From the USPTO record |
| US 6,030,611 | Therapeutic SOD compositions and uses thereof Formerly held Term ended Term ended Feb 28, 2017 · From the USPTO record | Term ended | Term ended Feb 28, 2017 | From the USPTO record |
| US 6,010,875 | Expressions plasmids containing the deo promoter, and bacterial hosts containing the plasmids Formerly held Term ended Term ended Jul 25, 2016 · From the USPTO record | Term ended | Term ended Jul 25, 2016 | From the USPTO record |
| US 6,090,799 | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 Formerly held Term ended Term ended Jun 22, 2015 · From the USPTO record | Term ended | Term ended Jun 22, 2015 | From the USPTO record |
| US 7,132,510 | Specific Human Antibodies for Selective Cancer Therapy Formerly held Lapsed on the fee record Ended Nov 7, 2014 · High confidence | Lapsed on the fee record | Ended Nov 7, 2014 | High confidence |
| US 6,670,351 | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 Formerly held Term ended Ended no later than Oct 20, 2012 · From the USPTO record | Term ended | Ended no later than Oct 20, 2012 | From the USPTO record |
| US 6,121,426 | Fibrin binding domain polypeptides and uses and methods of producing same Formerly held Lapsed on the fee record Ended Sep 19, 2012 · From the USPTO record | Lapsed on the fee record | Ended Sep 19, 2012 | From the USPTO record |